Banfield C C, Redburn J C, Dawber R P
Department of Dermatology, The Oxford Radcliffe Hospital, Old Road, Headington, Oxford OX3 7LT, U.K.
Br J Dermatol. 1998 Aug;139(2):276-9. doi: 10.1046/j.1365-2133.1998.02365.x.
Our population-based study establishes epidemiological data on age-specific incidence rates, clinical presentation, Breslow microstaging, treatment and survival of nail apparatus melanoma (NAM) patients in England. Four cancer registries, covering a population of 10.6 million, recorded 105 cases of NAM during the period 1984-93. During the same decade there was a total of 7585 patients with cutaneous melanoma and NAM represents 1.4% of all cutaneous melanoma. The incidence rate of NAM in English patients is 0.1 per 100,000 of the population per annum. Amelanotic melanoma was the clinical presentation in 24 of our NAM cases. The overall prognosis is poor with an observed 5 year survival of only 51%. Patients with NAM less than 2.5 mm Breslow depth have a 5 year survival of 88% and are twice as likely to survive compared with those with tumours greater or equal to 2.5 mm in thickness (P < 0. 05). NAM patients are best managed by a multidisciplinary team approach in a few key skin cancer centres.
我们基于人群的研究建立了关于英国甲襞黑色素瘤(NAM)患者的年龄特异性发病率、临床表现、Breslow微分期、治疗及生存情况的流行病学数据。四个癌症登记处覆盖了1060万人口,在1984年至1993年期间记录了105例NAM病例。在同一十年间,共有7585例皮肤黑色素瘤患者,NAM占所有皮肤黑色素瘤的1.4%。英国患者中NAM的发病率为每年每10万人中有0.1例。无色素性黑色素瘤是我们105例NAM病例中的24例的临床表现。总体预后较差,观察到的5年生存率仅为51%。Breslow深度小于2.5mm的NAM患者5年生存率为88%,与肿瘤厚度大于或等于2.5mm的患者相比,生存可能性是其两倍(P<0.05)。NAM患者最好在少数几个关键的皮肤癌中心通过多学科团队方法进行管理。